Social Survey Research Information Co., Ltd.

SSSRI Drug Price Database
Addition of the “Price Maintenance Premium (PMP)” and
Deductible information and Revision of Annual Fees （24/12/26）
Announcement about survey for physicians' survey database "PatientsMap" US version to be conducted （24/08/08）
Rare Disease Day 2024
--- Focusing on treatment gaps in rare diseases --- （24/02/29）
Analysis of the prevalence of digital therapeutics (DTx) among physicians and the expectations they have
--PatientsMap 2023 Japan version— （24/01/30）
PatientsMap 2023 Japan version is now available （23/10/25）
Analysis of the potential for administering new drugs in terms of the number of patients
- from PatientsMap2022JP version - （23/09/07）
Analysis of the potential for administering new drugs in terms of the number of patients
- from PatientsMap2022JP version - （23/07/21）
PatientsMap 2022 US version now available （23/02/02）
PatientsMap 2022 Japan version now available （22/11/11）
Analysis by scale of hospitals and cities by the top 10 companies in China in terms of sales rep activities (6 foreign-funded and 4 domestic-funded). （22/08/25）
PatientsMap 2022 Japan Survey Begins. （22/06/28）
PatientsMap analysis of Chinese physicians’ needs for new drugs （22/06/09）
Launch of PatientsMap China 2022 （22/04/22）
Analysis of trends in the needs for new drugs with PatientsMap data （22/02/28）
Increase in symptoms of depression and anxiety worldwide due to COVID-19 （21/03/05）
Final Results of Cyberattack Incident Investigation （20/12/14）
PatientsMap database is now available in English. Try out the demo version! （20/09/02）
Launch of PatientsMap 2017 JP （17/12/07）
Market Potential with new product needs in USA （17/07/24）
China’s COPD market research report – now available （16/09/06）
CI Insight Report "Research of China’s COPD Market" （16/05/06）
Medical conditions with new product needs: A comparison of US vs. Japan through a large-scale physician survey (PatientsMap) Click here to see the full press release (PDF) （16/02/10）
SSRI CHINA completes its investment in HIMA, a Shanghai-based pharmaceutical market research company. Click here to see the full press research (PDF) （15/08/21）
We welcome HIMA as an SSRI group company （15/08/21）
Top unmet medical need: Obesity (US) vs. Dementia (Japan) （15/08/04）